Overview

Update
Status
Altheos has been closed
Total Equity Funding
$32.5M in 2 Rounds from 5 Investors
Headquarters:
South San Francisco, CA
Description:
Altheos was a biopharmaceutical company focused on the development of small molecule drugs.
Founders:
Categories:
Health Care, Biotechnology, Clinical Trials
Website:
http://altheos.net

Company Details

Update

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.

Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Funding Rounds (2) - $32.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Feb, 2012$12.5M / Series A3
Apr, 2010$20M / Series A5

News (2)

Update
DateNews
Feb 9, 2012Fierce Biotech - Altheos raises 12500000 in venture round
Apr 5, 2010Fierce Biotech - Glaucoma drug focus inspires $20M A round for Altheos

Offices/Locations (1)

Update
  • Office

    400 Oyster Point Boulevard

    Suite 108

    South San Francisco, CA 94080

    USA

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos